Prescient Therapeutics Ltd: Appendix 4D and Half Year Financial Report

ASXFeb 20 17:56 ET · Announcements

Prescient Therapeutics Resumes OmniCAR Program After Developing New Variants

MT NewswiresJan 23 02:02 ET

Prescient Therapeutics Secures US FDA Clearance for Phase Two Lymphoma Trial; Shares Down 4%

MT NewswiresDec 26, 2024 20:19 ET

Prescient Therapeutics Welcomes US FDA Allowance of Investigational New Drug Application for PTX-100 Phase 2 Clinical Trial | ASX:PTX, OTC:PSTTF

Proactive InvestorsDec 22, 2024 18:11 ET

Prescient Therapeutics Appoints Experienced Pharmaceuticals Executive James McDonnell as CEO | ASX:PTX, OTC:PSTTF

Proactive InvestorsDec 16, 2024 20:29 ET

Prescient Therapeutics CEO Yatomi-Clarke Steps Down; Will Remain Available as a Consultant

Investing.com Sep 11, 2024 19:55 ET